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.2012.05.0Abstract Schistosomiasis is a debilitating disease affecting approximately 600 million people in 74
developing countries, with 800 million, mostly children at risk. To circumvent the threat of having
praziquantel (PZQ) as the only drug used for treatment, several PZQ derivatives were synthesized,
and drugs destined for other parasites were used with success. A plethora of plant-derived oils
and extracts were found to effectively kill juvenile and adult schistosomes, yet none was progressed
to pre- and clinical studies except an oleo-gum resin extracted from the stem of Commiphora molmol,
myrrh, which action was challenged in several trials. We have proposed an essential fatty acid, a com-
ponent of our diet and cells, the polyunsaturated fatty acid arachidonic acid (ARA) as a remedy for
schistosomiasis, due to its ability to activate the parasite tegument-bound neutral sphingomyelinase,
with subsequent hydrolysis of the apical lipid bilayer sphingomyelin molecules, allowing access of
speciﬁc antibody molecules, and eventual worm attrition. This concept was convincingly supported
using larval and adult Schistosoma mansoni and Schistosoma haematobium worms in in vitro exper-
iments, and in vivo studies in inbred mice and outbred hamsters. Even if ARA proves to be an entirely
effective and safe therapy for schistosomiasis, it will not prevent reinfection, and accordingly, the
need for developing an effective vaccine remains an urgent priority. Our studies have supported
the status of S. mansoni calpain, glutathione-S-transferase, aldolase, triose phosphate isomerase,
glyceraldehyde 3-phosphate dehydrogenase, enolase, and 2-cys peroxiredoxin as vaccine candidates,
as they are larval excreted-secreted products and, contrary to the surface membrane molecules, are
entirely accessible to the host immune system effector elements. We have proposed that the use of
these molecules, in conjunction with Th2 cytokines-inducing adjuvants for recruiting and activating
eosinophils and basophils, will likely lead to development and implementation of a sterilizing vaccine
in a near future.
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02Schistosomiasis
Schistosomiasis, a debilitating disease endemic in 74 countries
of the developing world, does not affect 207 million people as
reported in 2006 [1], as recent articles document infection of
391–597 million people, with 800 million, mostly children, at.V. All rights reserved.
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not cause the annual loss of between 1.7 and 4.5 [1], but be-
tween 24 and 56 [2], and up to 70 [3,4] million disability ad-
justed life years. Egyptian health authorities and public
media continuously advocate the near elimination of schistoso-
miasis from Egypt, statement that was not denied by the pa-
tients in rural populations because of the stigma of poverty
and social status inferiority linked to this infection. Yet, sev-
eral articles document that Egypt has more than 10 million
persons infected with schistosomes [2,5,6]. An article published
in 2012 reports that Egypt is the MENA (Middle East North
African) country with the highest prevalence (7.2 out of 80.4
million people, about 9%) of schistosomiasis [7]. This contro-
versy must be laid at rest via generation or publication of
objective, and scientiﬁcally valid data regarding the present
prevalence of schistosomiasis in Egypt.
Schistosomiasis is caused by the platyhelminth worms of
the genus Schistosoma, trematodes that live in the bloodstream
of humans and animals. Three species (Schistosoma mansoni,
Schistosoma haematobium andSchistosoma japonicum) account
for the majority of human infections. Cercariae break out of
the snail tissues into the water, swimming actively till dying
or penetrating the unbroken skin of humans or animals, the
deﬁnitive host, where they change into schistosomula. During
the ﬁrst 24 h after infection, nearly 90% of S. mansoni and S.
haematobium schistosomula are present only in the blood-free,
lymph-free epidermis. Majority of schistosomula are found in
the dermis only after 48 h, and they appear to reach the dermal
vessels around 72 h after infection [8,9]. Once in the blood cap-
illaries, the schistosomula are carried passively by the blood
ﬂow till reaching the right heart and then the lungs. Depending
on the species, schistosomula stay inside the pulmonary capil-
laries from 3 to 16 days, where they change into much longer
and slender organisms, such a shape that enables them to tra-
verse the thin pulmonary capillaries to the left heart and the
systemic circulation [10]. Following this period, the larvae
make their way to the liver via the splanchnic vasculature.
Upon reaching the liver, schistosomula start feeding and grow-
ing by active cell division. Once they reach maturity the worms
start pairing, between 28 and 35 days post-infection. The
paired adults migrate out of the liver, with the male carrying
the female, to where they will ﬁnally reside in the mesenteric
veins (S. mansoni), or in the pelvic venous plexus and veins
around the bladder (S. haematobium) [11,12]. Massive numbers
of daily deposited eggs must traverse the walls of the blood
venules to enter the lumen of the intestine or bladder, to be ex-
creted with the feces or urine. The morbidity associated with
schistosomiasis results from the immunologic reactions to
egg-derived antigens, beside the mechanical and toxic irritation
caused by eggs trapped in the wall of blood vessels [11–14].
Some of the most common pathological changes seen in
chronic schistosomiasis infections include bleeding into the
intestine or urinary system, liver and spleen enlargement, and
periportal ﬁbrosis [11–14]. A connection between the chronic
urinary form of schistosomiasis and bladder cancer is sus-
pected [12,14].
In addition to the severe sequelae of schistosomiasis, the
infection, even light, predisposes the host to, and accelerates
the course and increases the severity of, infection with human
immunodeﬁciency [15,16], and hepatitis B and C (HCV) viruses.
For example, Egypt has the highest prevalence of HCV being
>15% in rural areas where schistosomiasis is endemic, wherebyco-infection with schistosomiasis causes more severe liver dis-
ease than infection with HCV alone [17,18]. Infection with
schistosomes renders the host particularly susceptible to myco-
bacteria, and protozoa, especially of the genus Plasmodium,
Leishmania, Toxoplasma, and Trypanosoma [reviewed in 19].
Schistosomicides
Antimonial compounds, usually used for cure of leishmaniasis,
have been the cornerstone of schistosome chemotherapy for
about 50 years. Their mode of action is believed to be strong
inhibition of the schistosome phosphofructokinase (the enzyme
catalyzing the conversion of fructose-6-phosphate to fructose-
1,6-diphosphate) at concentrations 65–80 times lower than
those effective against the human enzyme [20]. This wide differ-
ence indicates that inhibition of host phosphofructokinase can-
not be the only cause for the antimonial drugs’ excessive toxicity
and severe side effects, which have rendered them now obsolete.
The organophosphorus insecticide 2,2,2-trichloro-1-
hydroxyethyl dimethyl phosphonate was slightly modiﬁed to
give rise to metrifonate (O,O-dimethyl-2,2,2-trichloro-1-
hydroxyethylphosphonate), which has showed constant activ-
ity against S. haematobium. Metrifonate is administered orally,
and is metabolized leading to several byproducts, among which
dichlorvos is the most potent, inducing schistosome acetylcho-
linesterase inhibition with subsequent reversible paralysis of the
worm [21,22]. Paralyzed schistosomes lose their hold on the in-
ner wall of blood vessels and are swept away with the blood
stream, S. mansoni to the liver and S. haematobium to the lungs
via the vena cava. Upon drug concentration decrease, S. man-
soni are capable of regaining their original location in the mes-
enteric veins, whereas S. haematobium remain trapped in the
lungs [23]. This might explain that metrifonate mediates killing
of S. haematobium but not S. mansoni. It is of note that the drug
also depresses host plasma and erythrocyte cholinesterase,
explaining the severe side effects: fatigue, muscular weakness,
tremor, sweating, fainting, diarrhea, nausea, vomiting, bron-
chospasm, consequences of cholinergic stimulation. Besides,
three oral doses are absolutely required to reach a cure rate
of 90%. This might explain why metrifonate has been taken
out of the World Health Organization (WHO) list of essential
drugs [24], leaving oxamniquine and praziquantel the only
available drugs for treating schistosomiasis.
Oxamniquine, 1,2,3,4-tetrahydro-2-(isopropylamino)met-
hyl(-)7-nitro-6-nitro-quinoline methanol, when administered
orally is effective against S. mansoni, male worms beingmore af-
fected than females, while it has no effect on S. haematobium. A
single, two or three oral doses of 20 mg/kg each, are needed for a
cure rate of 80–90%, depending on the geographic region. After
a curative dose in healthy volunteers, peak plasma concentra-
tions of 1–4 mg/L are reached in 1–4 h and the plasma half-life
is of the order of 1.5–2 h. Oxamniquine concentrations of 40 lg/
mL are also lethal to adult S. mansoni in vitro [25,26]. It is now
believed that oxamniquine undergoes esteriﬁcation by a sulfo-
transferase uniquely present in sensitive schistosomes. The ester
spontaneously dissociates, yielding an electrophilic reactant
capable of alkylating schistosome DNA, with subsequent inhi-
bition of DNA and RNA synthesis; the absence of this enzyme
in mammals, including humans, explains the low toxicity of
oxamniquine [27]. Resistance to oxamniquine has emerged in
various foci, perhaps due to a mutation in the schistosome gene
encoding the critical bioactivating (esterifying) enzyme [27,28].
Schistosomicides and Vaccines 469Oxamniquine is used on a large scale only in Brazil. For the rest
of the world, a single drug is now in use for treatment of schis-
tosomiasis: praziquantel.
Praziquantel (PZQ), a pyrazino-isoquinoline derivative is
practically insoluble in water, sparingly soluble in ethanol,
but very soluble in chloroform and dimethylsulfoxide. It is
the drug of choice for treatment of all ﬁve species of human
schistosomes, leading to cure rates of 60–90% in different epi-
demiological settings [29,30]. Adult schistosomes exposed
in vitro to 1–3 lM PZQ undergo almost immediate spastic
paralysis. In parallel, vacuolization of parts of the tegument
and surface blebbing occur, especially in male worms (Table 1).
All worms die thereafter. These reproducible ﬁndings indicate
that adult schistosomes bind PZQ, and that PZQ per se is
schistosomicidal [31]. In vivo, plasma concentrations of 1–
10 lM are readily reached after a standard curative dose. In
vivo, PZQ-induced muscle contraction and tegumental lesions
produce a loss of attachment to the endothelial veins and dis-
lodgment to the liver. Host cells of the defense system attach to
the tegumental vacuoles and start to penetrate to the interior
of the parasite early after treatment [28,32–34].
Despite that the initial effects of the drug included a rapid
inﬂux of calcium into the worm and calcium-dependent muscle
contraction and paralysis, the exact mode of action of PZQ is
not known as yet [35–38], and the PZQ receptor on schisto-
somes remains elusive [38,39]. One hypothesis to explain
PZQ mode of action is that this drug inserts itself in the mem-
brane producing lipid phase transition [40] and subsequent
destabilizing effects on the membrane [41]. It is certainly doc-
umented that PZQ interacts with the surface tegument and sev-
ers it dramatically [42].
Control initiatives in numerous countries, including Egypt,
rely on large-scale administration of PZQ [43–47]. Therefore,
reports of low drug efﬁcacy [48–50] and schistosome resistance
to the drug [39,51–55] have raised intense alarm. The likely
possibility that PZQ binds and polymerizes schistosome and
mammalian actin [56–60] should preclude its use in children,
pregnant women, and individuals with vascular diseases [61].
Novel therapeutic approaches
PZQ derivatives and combination chemotherapy
Intense efforts are now directed at circumventing the ﬂaw of
having a single drug for such a dreadful infection via synthesiz-Table 1 Schistosomicides target and mechanism of action.
Drug Mode of action
Antimonials Inhibition of schistoso
Metrifonate Schistosome acetylcho
Oxamniquine Mediates inhibition of
Praziquantel Still elusive; binding t
Tegument disruption?
Binding and polymeri
Exposure of surface m
Artemether Interacts with haemin
Meﬂoquine Inhibits hemozoin for
Acyclic nucleotide analogues Inhibit parasite DNA
Oxadiazoles Inhibit parasite thiore
Trioxaquines Alkylation of, and sta
Myrrh Worm uncoupling anding derivatives of PZQ [39,62] and benzodiazepine schistoso-
micides [63], and examining their schistosomicidal activity
in vitro and in vivo. Additionally, attempts were conducted to
use PZQ in combination with other potential schistosomicides
such as artemether [64–68], or hepatoprotective remedies
[69,70] in an aim to reduce the PZQ dose, potentiate its schist-
osomicidal action, and alleviate side effects in experimental
hosts.
Novel drugs
Several drugs targeting other parasites were tested for potential
schistosomicidal activity (Table 1). The anti malarial drug
artemether, a methoxy derivative of artemisinin, has been
shown to be active against S. japonica, S. mansoni, and S. hae-
matobium in experimentally infected animals [71]. A single oral
injection of 400 mg/kg artemether to mice infected with
approximately 80 cercariae of S. mansoni 21 (pre-patent) or
49 (patent period) days earlier led to 71–81% reduction in total
worm burden [72–75]. Meﬂoquine, another anti-malarial drug,
was also found to have signiﬁcant anti-schistosome activity
in vitro, and in vivo as well, as a single dose (200 or 400 mg/
kg), administered orally to mice infected with adult S. mansoni,
resulted in high worm burden reductions of 72.3–100% [76,77].
It has been shown that artemether interacts with haemin to ex-
ert a toxic effect on schistosomes, while meﬂoquine is believed
to inhibit hemozoin formation. Yet, there are objections
regarding a possible interference with the primary use of
artemether and meﬂoquine as antimalarials [71–77]. Trioxol-
anes, which were considered for their potent anti-malarial
activity, showed signiﬁcant schistosomicidal activity in vitro
and in vivo against S. mansoni and S. japonicum [78]. Acyclic
nucleotide analogues, such as (S)-9-[3-hydroxy-2-(phosphono-
methoxy) propyl]adenine [(S)-HPMPA] and their derivatives,
possess effective broad-spectrum activity against many viruses
via inhibition of DNA polymerase and/or reverse transcriptase,
and were found to be actively schistosomicidal in vivo and
in vitro [79,80]. The anti-microbial and anti-cancer oxadiazoles,
which are ﬁve-membered heteroaromatic rings containing two
carbons, two nitrogens, and one oxygen atom, have been found
to possess inhibitory activity against S. mansoni and S. japoni-
cum redox protein thioredoxin-glutathione reductase [81,82].
Trioxaquines, hybrid drugs containing a 1,2,4-trioxane and a
4-aminoquinoline, initially developed against malaria, exhibit
a dual mode of action: alkylation of heme with the trioxaneReferences
me phosphofructokinase [20]
linesterase inhibition and paralysis [22]
parasite DNA and RNA synthesis [27]
o parasite calcium channels? [35–38]
[40–42]
zation of actin? [56–60]
embrane antigens [33,34]
[71–74]
mation [76]
polymerase? [79,80]
doxin-glutathione reductase [81,82]
cking with, heme [83]
extravasation [98]
Fig. 1 Arachidonic acid structure.
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moiety, leading to inhibition of hemozoin formation in vitro,
thus explaining their potent anti-S. mansoni activity in vitro
and in vivo [83]. Imidazolidines, pentagonal heterocyclic com-
pounds with broad biological anti-microbial and anti-fungal
activities, were considered for treatment of schistosomiasis
because of their potent in vitro schistosomicidal effects [84].
Of great interest is the class of compounds targeting schisto-
some histone modifying enzymes, namely histone acetyltrans-
ferases and histone deacetylases, and leading to parasite
apoptosis and death in in vitro cultures [85].
Plant-derived schistosomicidal compounds
A different approach to therapy of schistosomiasis relied on
plants known for medicinal effects. Extracts and oils of several
medicinal plants were tested for potential therapeutic activity
against schistosome infection [86,87], and were exhaustively
compiled in excellent reviews [88–91]. Curcumin, themajor con-
stituent in the rhizome ofCurcuma longa has been shown to dis-
play potent schistosomicidal activities in vivo and in vitro
against adult S. mansoni worms [92–96]. The most successful
product was myrrh, an oleo-gum resin extracted from the stem
ofCommiphora molmol [97], believed to affect schistosomemus-
culature, leading to uncoupling of male and female couples and
their extravasation to the liver tissue [98]. The product has been
licensed for human use by the EgyptianMinistry of Health, and
introduced in the Egyptian market in the form of gelatinous
capsules by the pharmaceutical company, Pharco (Alexandria,
Egypt) under the name ofMirazid. However, conﬂicting reports
on its efﬁcacy shed doubts upon the usefulness of its use as a no-
vel therapy for schistosomiasis [98–103].
Arachidonic acid, a novel remedy for schistosomiasis
Mode of action
Our approach to the therapy of schistosomiasis is entirely no-
vel and is herein clariﬁed. Developing and adult schistosomes
are covered by the tegument, a 2–4 lm thick syncytium. The
innermost membrane of the tegument is a conventional mem-
brane (the basal membrane), whereas the outer membrane on
the syncytium is trilaminate in cercariae. By about 3 h after
penetration, the trilaminate outer membrane of the cercariae
is gradually replaced by a unique heptalaminate membrane,
widely believed to cause protection against elements of the host
immune system. Notably, the surface membrane at the para-
site/host interface consists of two tightly apposed bilayers,
the inner and outer bilayers, each of which is composed of in-
ner and outer leaﬂets [104]. As for conventional plasma mem-
branes, proteins are embedded in schistosome outer and inner
lipid bilayers among phosphoglycerides, cholesterol and sphin-
gomyelin molecules [105]. Conversely from conventional plas-
ma membranes, proteins in the schistosome outer lipid bilayer
are concealed, hidden, and totally inaccessible to host antibod-
ies. We have recently shown that this major immune evasion
phenomenon is due to the sphingomyelin of the outer lipid bi-
layer, likely via concealment of surface membrane proteins be-
hind a tight barrier of hydrogen bonds sphingomyelin readily
forms with water molecules [106–110].
Sphingomyelin hydrolysis is catalyzed by a group of en-
zymes called sphingomyelinases, yielding ceramide and phos-
phorylcholine. Many sphingomyelinase activities have beenidentiﬁed and may be classiﬁed into two main groups. The acid
forms function at an optimal pH of 4.5, and are found in the
cell acidic compartments. The neutral forms function at a neu-
tral pH and are found in different locations within the cell,
especially the outer membrane [111]. Tegument-bound neutral
sphingomyelinase (nSMase) activity is optimal at pH > 7.4,
exhibits an absolute dependence on magnesium or manganese
(2 and 10 mM for Mg2+ and up to 2.5 mM for Mn2+), and is
readily inhibited by the compound GW4869 [112]. Like mam-
malian nSMase [111–113], S. mansoni tegument-associated
nSMase activity is increased several folds, in vitro and
in vivo, by polyunsaturated fatty acids, especially arachidonic
acid (ARA) [114–116]. We have documented that in vitro treat-
ment of lung-stage schistosomula and adult worms with unsat-
urated fatty acids, especially ARA, leads to exposure of
otherwise hidden surface membrane antigens to speciﬁc anti-
body binding [106,109,110,117]. More importantly, feeding
S. mansoni or S. haematobium-infected mice with unsaturated
fatty acids-enriched food led to signiﬁcant (P< 0.02) decrease
in worm burden [109]. Accordingly, we proposed that ARA
may represent a novel remedy for schistosomiasis.
Arachidonic acid properties
Arachidonic acid (ARA) is an omega-6 fatty acid: 20:4(x-6),
with a 20-carbon chain and four cis double bonds; the ﬁrst
double bond located at the sixth carbon from the omega end
(Fig. 1). It is present in the phospholipids of membranes of
the body’s cells, and is abundant in the brain. The ARA four
cis double bonds (Fig. 1) are the source of its ﬂexibility, keep-
ing the pure fatty acid liquid, even at subzero temperatures,
and helping to give mammalian cell membranes their correct
ﬂuidity at physiological temperatures. The double bonds are
also the key to the propensity of ARA to react with molecular
oxygen. This can happen nonenzymatically, contributing to
oxidative stress, or through the actions of three types of oxy-
genase: cyclooxygenase (COX), lipoxygenase (LOX), and cyto-
chrome P450 [118,119].
Proposing intake of exogenous ARA could be met with
awe, as ARA may be metabolized to end products that pro-
duce pain and inﬂammation, namely the prostaglandins
(COX pathway), which are mediators of the vascular phases
of inﬂammation, are potent vasodilators, and increase vascular
permeability; prostacycline (vasodilator and reduces platelet
aggregation); thromboxane (increases vasoconstricton and
platelet aggregation); and leukotrienes (LOX pathway) that
are important mediators of inﬂammation. Of great concern
too, is the fact that exogenous ARA is acted upon by COX
and LOX enzymes, despite that many of which are located
on the endoplasmic reticulum or nuclear membrane [118,119].
We have embarked on use of ARA for schistosomiasis ther-
apy sure of the fact that ARA is an essential constituent of
membrane lipids, and is the base material used by the body
to synthesize a key series of hormones referred to collectively
as dienolic prostaglandins (PG) that include the prostaglandins
PGE2 and PGF2a. Proper development of the brain, retina
and other body tissues depends upon provision of ARA either
Schistosomicides and Vaccines 471directly in the diet or through synthesis from linoleic acid
(LA). Additionally, ARA is an essential fatty acid, which is
consumed in our regular diets. It is found mainly in lean meat,
egg yolks and some ﬁsh oils. Tissue ARA pools originate from
the diet, and from hepatic and extrahepatic desaturation–elon-
gation of dietary LA; in humans who ingest 0.2–0.3 g of ARA
and 10–20 g of LA per day on a Western diet the formation of
ARA from LA exceeds the dietary supply of ARA [120]. In-
deed, most evidence supports that ingestion of moderate
amounts of ARA is not disadvantageous. In a series of studies,
humans ingested a diet containing 1.7 g of ARA per day for
50 days, and were then extensively studied. Dietary ARA at
these levels nearly doubled ARA levels in the plasma phospho-
lipids and cholesteryl ester, whereby ARA mainly replaced
LA, which was reduced by 20%. Some increases in platelets,
red blood cells, and tissue lipids were also found, but no signif-
icant increase in ARA was seen in adipose tissue triglycerides
and phospholipids. The plasma free fatty acids showed a small
but statistically signiﬁcant rise in the ARA level. No harmful
effects could be proven during the studies, although an in-
creased production of eicosanoids was observed [121].
It is of note that ingestion of x-3 essential fatty acids,
namely EPA (eicosapentaenoic acid) entirely protects from
any inﬂammatory effect ARA might elicit, by displacement,
competitive inhibition, and direct counteraction. Docosahexa-
enoic acid (DHA) was reported to have an effect similar to
EPA [122,123]. DHA is an omega-3 essential fatty acid,
22:6(x-3), with a 22-carbon chain and six cis double bonds;
the ﬁrst double bond located at the third carbon from the ome-
ga end. Fortunately, Martek Biosciences Corporation recently
produced infant formulas and capsules containing ARA
(ARASCOR) and DHA. Using controlled fermentation condi-
tions, Martek Biosciences obtains ARA from the soil fungus
Mortierella alpina, and DHA from the non-photosynthetic
marine micro-algae Crypthecodinium cohnii, products of pro-
ven entire safety [124]. Molecular Nutrition Company devel-
oped X-Factor, Arachidonic Acid as a food supplement
during exercise. X FactorTM Arachidonic Acid is provided in
the form of Softgels containing each 250 mg ARA, whereby
1 to 5 Softgels are recommended per day. In addition, ARA
(ARASCOR, Martek Biosciences Corporation) was recently
allowed to be added to infant formulas.
Schistosomicidal effects in vitro and in vivo
In our studies, pure ARA from Sigma was used for in vitro and
preliminary in vivo studies, while ARA from Martek was used
for in vivo studies [125,126]. We have demonstrated that 5 mM
pure ARA (Sigma) leads to irreversible killing of ex vivo 1, 3,
4, 5, and 6 week-old S. mansoni and 9, 10 and 12 week-old S.
haematobium worms, within 3–4 h, depending on the parasite
age, even when worms were maintained in up to 50% fetal calf
serum. ARA-mediated worm attrition was prevented by nSM-
ase inhibitors such as CaCl2 and GW4869. Scanning and trans-
mission electron microscopy revealed that ARA-mediated
worm killing was associated with spine destruction, membrane
blebbing, and disorganization of the apical membrane struc-
ture [125]. ARA-mediated S. mansoni and S. haematobium
worm attrition was reproduced in vivo whereby a series of 20
independent experiments using BALB/c or C57BL/6 mice, or
hamsters indicated that ARA in a pure form (Sigma), included
in infant formula (Nestle), or capsules (X Factor, Molecular
Nutrition) consistently led to between 50% and 80% decreasein S. mansoni or S. haematobium worm burden [125,126].
ARA-mediated attrition in vivo appeared to be associated with
high titers of serum antibodies to tegumental antigens. In sup-
port, serum antibodies from patently-infected and ARA-
administered hamsters readily bound to the surface membrane
of ARA-treated, but not untreated, adult worms, as judged by
indirect membrane immunoﬂuorescence. More importantly,
addition of serum antibodies and peripheral blood mononu-
clear cells signiﬁcantly enhanced ARA-mediated adult worm
attrition in vitro [126]. Immune responses to adult worm tegu-
mental antigens are certainly more powerful in adults and chil-
dren with patent infection than in hamsters, and ARA is
already marketed for human use in USA and Canada for prop-
er development of newborns, and muscle growth of athletes.
Accordingly, it is recommended to start pre-clinical and clini-
cal studies in human volunteers for development of ARA as a
safe and cost-effective remedy to schistosomiasis, especially
that no ARA-related adverse effects were seen in any experi-
ment in mice or hamsters. Indeed, no changes were observed
between untreated and ARA-treated experimental hosts in ser-
um levels of triglycerides or cholesterol, number of erythro-
cytes or platelets, thrombin or prothrombin values in accord
with the numerous reports documenting the entire safety of
ARA ingestion [125,126].
Vaccine candidates and trials
The possibility of developing an effective vaccine for schistoso-
miasis stemmed from the highly signiﬁcant protection obtained
in experimental hosts using irradiated cercariae [reviewed in
127] and from the identiﬁcation of humans resistant to
schistosomiasis. Individuals classed as ‘‘endemic normals’’ are
repeatedly exposed to infective cercariae and yet have no record
of previous or current infection, and appear uninfected as
judged by repeated stool examination. ‘‘Resistant’’ subjects
are those whose stool and urine samples remain negative for
eggs or show very low levels of reinfection following drug
treatment of previous S. mansoni or S. haematobium infection
despite unequivocal evidence of continued and high contact
with schistosome-contaminated watersources [128–135]. The
ﬁrst subunit vaccine candidate antigens discovery was based
on these models, whereby antibodies from irradiated cercariae
(RA) vaccine-immunized mice and resistant individuals were
used to screen schistosome cDNA libraries. These studies led
to identiﬁcation of S. mansoni irradiation associated vaccine
antigen, IrV 5 [136,137], glutathione-S-transferase, GST
[138,139], triose phosphate isomerase, TPI [140–142], paramy-
osin [131,143,144], fatty acid binding protein, Sm 14, [145], the
surface membrane antigen Sm23 [146–148], the calcium-
dependent cysteine protease, calpain [4,149], and glyceralde-
hyde 3-phosphate dehydrogenase [130,150,151]. We have
challenged the unique use of serum antibodies for selection of
schistosome candidate vaccine antigens, because of the
extensive cross-reactivity of B cell epitopes and the need to
ascertain that the selected antigen is able to induce T cell help.
Accordingly, we have used the T cell western technique to
examine the proliferative and cytokine production activity of
mouse spleen cells (SC) and human peripheral blood mononu-
clear cells (PBMC) in response to electroseparated and electro-
blotted soluble adult worm antigens (SAWA). Extensive
analyses of the T and B cell reactivity of gamma or ultravio-
let-irradiated cercariae-immunized inbred and outbred mice
472 R.A.F. El Ridi and H.A.-M. Tallimato separated SAWA antigens [152–154] led to identiﬁcation of
S. mansoni enolase [152,155] and calreticulin [156] as the anti-
gens preferentially recognized by RA vaccinated mice. Studies
using PBMC and sera obtained from endemic resistant humans
or individuals resistant to reinfection after PZQ treatment
ended into rediscovery of glyceraldehyde 3-phosphate dehydro-
genase (SG3PDH) as potential candidate vaccine antigen
[134,135]. The cDNA encoding the full length molecule was
cloned and expressed by Charles Shoemaker, and SG3PDH
joined the group of candidate vaccine antigens, IrV5, paramy-
osin, GST, TPI, Sm14, Sm23, and calpain selected by the World
Health Organization (WHO) for in vitro and in vivo trials. The
in vitro studies using PBMC and sera of Egyptian [157] and Bra-
zilian [158] donors led to inconclusive answers, while the in vivo
trials in inbred mice indicated that none of the vaccine candidate
antigens induced higher than 40% reduction in challenge worm
burden, the benchmark set by the WHO for progression of
schistosome vaccine antigens into clinical trials [159].
The S. mansoni fatty acid-binding protein, Sm14 antigen
stands out, due to its steady progress towards ﬁeld trials. Work
has now progressed to the scale-up level and an industrial pro-
duction process has successfully been put in place [160]. S.
mansoni calpain in recombinant or DNA constructs appeared
as successful, inducing protection levels higher than 50% in
C57BL/6 mice and baboons vaccinated with the immunogen
emulsiﬁed in complete Freund’s adjuvant, alum, or CpG
[4,161,162]. Numerous protection trials were subsequently per-
formed in outbred and inbred mice using SG3PDH, in a re-
combinant or peptidic form. Peptides with lowest homology
to the human counterpart synthesized as linear, monopeptidic
or dipeptidic multiple antigen peptide (MAP) constructs, or
full length recombinant SG3PDH were used in conjunction
with complete (CFA) or incomplete (IFA) Freund’s adjuvant,
alum, or TiterMax adjuvant, leading to protection levels be-
tween 10 and 35% [163–166 and references therein].
The failure with SG3PDH was ascribed to the fact that
the potential candidate vaccine antigens must be located at
the host-parasite interface to be accessible to antibody-depen-
dent cell-mediated cytotoxicity (ADCC) the once thought
plausible mechanism of schistosome elimination. We have
used as immunogen the S. mansoni glucose transporter,
SGTP4, cloned and sequenced by Patrick Skelly and Charles
Schoemaker [167]. We have circumvented the poor immuno-
genicity and strong hydrophobicity of the molecule that pos-
sesses 12 transmembrane domains, by using the large
extracellular loop in a recombinant form, and the other extra-
cellular stretches as synthetic linear peptides. Extensive stud-
ies in C57BL/6, BALB/c, and outbred CD1 mice immunized
with SGTP4 in a recombinant or peptidic form in conjunc-
tion with CFA and IFA resulted into lack of protection
against challenge S. mansoni infection, despite considerable
speciﬁc humoral and cellular immune responses [168]. More
recently, the S. mansoni integral surface membrane proteins
tetraspanins (TSP)-1 and TSP-2 encoding cDNA were cloned,
sequenced, and expressed and shown to elicit protection levels
of 57% and 64% (TSP-2) and 34% and 52% (TSP-1) for
mean adult worm burdens and liver egg burdens, respectively,
over two independent trials in CBA/CaH mice [169]. The pro-
tection levels were not reproduced using S. japonicum coun-
terpart, whereby mice immunized with the recombinant
protein of a single TSP-2 subclass showed no protection,while immunization with a mixture of seven recombinant
TSP-2 subclasses provided a moderate protection [170]. The
failure in inducing consistent protection was ascribed to poly-
morphism in the extracellular site used for vaccination [170–
172]. A recent study used S. mansoni TSP-2 extracellular loop
2 region in conjunction with alum and CpG as adjuvants and
reported extremely variable protection levels against chal-
lenge infection within cohorts of highly inbred C57BL/6 mice
[173].
Novel prevention approaches
Up to today, there is no available vaccine for schistosomiasis.
One major reason for this failure resides in selecting unsuitable
vaccine candidates. Thus, it is not clear how the host immune
effector elements would eliminate parasites via interacting with
internal and cytosolic proteins such as paramyosin, fatty acid
binding protein, GST, TPI, or SG3PDH [164,174]. Addition-
ally, surface membrane antigens are hidden in the developing
larvae and adult worms and, hence, are entirely inaccessible
to the host immune system unless the parasite is suffering
excessive loss of tegument integrity and poised to die [106–
110,175–177]. Conversely, viable lung schistosomula excre-
tory–secretory products (ESP) are ideal potential vaccines.
ESP can readily play a central role in induction of local pri-
mary and memory immune responses, and are available targets
to the effector immune elements, mediating generation of im-
mune effectors, toxic radicals, and inﬂammatory cytokines
and cells that would directly target, surround, and pursue
the larvae while painstakingly negotiating the tight lung capil-
laries [178].
Accordingly, schistosomula were separated from BALB/c
lung 6 days after infection with cercariae of S. mansoni, iso-
lated free of host erythrocytes and lung cells, and cultured
for 48 h in protein-free medium under conditions that entirely
preserved the viability of larvae and any remaining cells. The
released ESP proteins were minute in quantity, corroborating
the results obtained with in vitro-grown lung larvae [179,180],
yet were highly immunogenic in BALB/c mice, inducing pro-
duction of speciﬁc antibodies, and expression of mRNA for
interleukin (IL)-12p40, interferon-gamma (IFN-c) and tumor
necrosis factor-alpha (TNF-a) [178]. Proteomic analysis of
the ESP molecules of 25, 28 and 40 kDa revealed sequences
belonging to innumerable rodent host-derived and a few S.
mansoni-speciﬁc proteins. S. mansoni fructose 1,6 biphosphate
aldolase (aldolase) and calpain were previously identiﬁed in
products released from in vitro-cultured S. mansoni lung schis-
tosomula [179]. Additionally, ex vivo lung stage schistosomula
were found to release TPI, GST, SG3PDH, and 2-cys-perox-
yredoxin (thioredoxin peroxidase, TPX) together with cyto-
solic molecules such as 14-3-3 protein homologue 1, actin
and histone. It is of note that calpain, aldolase, TPI, GST,
SG3PDH, TPX, and 14-3-3 protein homolog1 were detected
among soluble proteins of in vitro-grown 8 day S. mansoni
schistosomula [181], and secretions of S. mansoni cercariae
[182,183]. The status of many of these molecules as vaccine
candidates was made understood, as they are readily ex-
creted-secreted by intact larvae and are, hence, entirely acces-
sible to the host immune system effector elements [178].
In the vasculature, larval ESP and endothelial cells-
associated co-stimulatory molecules [184] induce T helper
Schistosomicides and Vaccines 473(Th) lymphocytes to release cytokines, which activate mono-
cytes, basophils, eosinophils, and neutrophils to target and
eliminate the migrating larvae. ESP interaction with speciﬁc
antibodies may also trigger myeloid cells towards participating
in the killing of migrating larvae. It is documented that larval
antigens induce Th1 immune responses [180,185,186]. Addi-
tionally, MAP construct containing S. mansoni TPI-derived
T- and B-cell epitopes was able to trigger naı¨ve donor immune
responses towards a type-1 cytokine proﬁle, consisting mainly
of IFN-c [187]. We have repeatedly observed that 14-3-3-like
antigen and TPX stimulate strong IFN-c and interleukin
(IL)-17-driven responses in SC obtained from naı¨ve mice and
mice 7 days after S. mansoni infection, while rSG3PDH and
TPX-derived peptide induced slightly lower levels of these
cytokines and a small amount of IL-4 [188].
Th1 inﬂammatory cytokines such as IFN-c and TNF-a
trigger monocytes and endothelial cells to release the poten-
tially larvacidal superoxide anions and oxygen and nitrogen
radicals, and the pro-inﬂammatory cytokines, IL-1, IL-6, and
IL-23 [189,190]. Monocytes activation generates high levels
of hydrogen peroxide and nitric oxide, which might be lethal
to many parasites [191,192], but may induce others to tighten
their protective outer double lipid membrane, via inactivation
of tegument-associated neutral sphingomyelinase [110]. Addi-
tionally, activated neutrophils recruited to the site by ESP- in-
duced IL-17 [188,193] can release a range of toxic species and
web-like structures termed neutrophil extracellular traps that
entrap the larvae within the vasculature [189,190,194]. Eosino-
phils and basophils, activated via binding ESP-antibody com-
plexes or type 2 cytokines, may release larvacidal molecules
and pro-inﬂammatory mediators in the vicinity of the migrat-
ing larvae, and produce factors that alter the blood capillary
permeability via disrupting endothelial integrity [194]. Larval
ESP, however, are known to induce Th1 and Th17 cytokine-
driven responses, thus hindering the recruitment, and activa-
tion of eosinophils and basophils.
To engage eosinophils and basophils in the hunt of migrat-
ing larvae, outbred, akin to humans, mice were immunized
with 10 lg recombinant SG3PDH and 15 lg TPX-derived pep-
tide in conjunction with 10 lg of the cysteine protease papain,
or 200 ng of the type 2 cytokines, thymic stromal lymphopoie-
tin, IL-25, or IL-33 as adjuvant [195–200]. Two weeks later,
untreated, adjuvant controls, and immunized mice were chal-
lenged with 100 or 125 cercariae. Results of 8 separate exper-
iments indicated that these formulations elicited IgM, IgG1,
and IgA speciﬁc antibodies, and increase in ex vivo SC release
of IL-4 and IL-5, correlated with highly signiﬁcant (up to
P< 0.0001) reduction of 62–78% in challenge worm burden
[200].
Improvement of ESP selection, singly or in a combination,
and immunization regimen, namely ESP and type-2 cytokine
dose and injection site and schedule, will likely lead to a ster-
ilizing schistosomiasis vaccine in a foreseeable future.Acknowledgments
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